Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities: 2016-2024

Historic Total Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $264.7 million.

  • Akebia Therapeutics' Total Non-Current Liabilities rose 25.51% to $317.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $317.3 million, marking a year-over-year increase of 25.51%. This contributed to the annual value of $264.7 million for FY2024, which is 0.48% up from last year.
  • Per Akebia Therapeutics' latest filing, its Total Non-Current Liabilities stood at $264.7 million for FY2024, which was up 0.48% from $263.4 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Total Non-Current Liabilities ranged from a high of $371.1 million in FY2021 and a low of $263.4 million during FY2023.
  • Over the past 3 years, Akebia Therapeutics' median Total Non-Current Liabilities value was $264.7 million (recorded in 2024), while the average stood at $287.7 million.
  • Per our database at Business Quant, Akebia Therapeutics' Total Non-Current Liabilities increased by 10.48% in 2021 and then dropped by 21.40% in 2023.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Total Non-Current Liabilities stood at $335.9 million in 2020, then climbed by 10.48% to $371.1 million in 2021, then declined by 9.71% to $335.1 million in 2022, then decreased by 21.40% to $263.4 million in 2023, then increased by 0.48% to $264.7 million in 2024.